Indero hosted a well-attended event during the American College of Rheumatology (ACR) Convergence 2026 in Orlando, Florida. The November 9 session brought together biopharma industry leaders for a morning of insight and discussion. This year’s program focused on mitigating placebo response in rheumatology randomized controlled trials (RCTs).
Key themes:
- Mitigation of placebo responses in systemic lupus erythematosus (SLE) RCTs
- Placebo responses: What shapes trial results in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) RCTs
Presenters and panelists:
- Joan T. Merrill, MD, MACR, Oklahoma Medical Research Foundation
- Andreas Kerschbaumer, MD, PhD, Stanford University and Medical University of Vienna
- Juan Ovalles, MD, Senior Director, Rheumatology, Indero
- Pina D’Angelo, MSc, Chief Scientific Officer, Indero
Have questions about CRO services in rheumatology trials? Contact us.